These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24239472)

  • 1. Precision medicine for metastatic renal cell carcinoma.
    Sonpavde G; Choueiri TK
    Urol Oncol; 2014 Jan; 32(1):5-15. PubMed ID: 24239472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to targeted therapy in renal cell carcinoma.
    Eisengart LJ; MacVicar GR; Yang XJ
    Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequencing therapy in metastatic renal cell cancer.
    Escudier B; Gore M
    Semin Oncol; 2013 Aug; 40(4):465-71. PubMed ID: 23972710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
    Armstrong AJ; George DJ; Halabi S
    J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.
    Vano YA; Tartour E; Fournier LS; Beuselinck B; Mejean A; Oudard S
    Expert Rev Anticancer Ther; 2014 May; 14(5):523-42. PubMed ID: 24640949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biomarkers in advanced renal cell carcinoma.
    Maroto P; Rini B
    Clin Cancer Res; 2014 Apr; 20(8):2060-71. PubMed ID: 24526734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
    Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
    Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.
    Shinohara N; Abe T
    Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
    Coinu A; Petrelli F; Barni S
    Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
    Mulders P
    BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma.
    Funakoshi T; Lee CH; Hsieh JJ
    Cancer Treat Rev; 2014 May; 40(4):533-47. PubMed ID: 24398141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.
    Clement JM; McDermott DF
    Clin Genitourin Cancer; 2009 Aug; 7(2):E7-9. PubMed ID: 19692326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to targeted therapy in renal-cell carcinoma.
    Rini BI; Atkins MB
    Lancet Oncol; 2009 Oct; 10(10):992-1000. PubMed ID: 19796751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.